Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
295.27
+0.65 (0.22%)
Oct 9, 2025, 4:00 PM EDT - Market closed
Amgen Employees
Amgen had 28,000 employees as of December 31, 2024. The number of employees increased by 1,300 or 4.87% compared to the previous year.
Employees
28,000
Change (1Y)
1,300
Growth (1Y)
4.87%
Revenue / Employee
$1,247,036
Profits / Employee
$236,393
Market Cap
158.96B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
Dec 31, 2021 | 24,200 | -100 | -0.41% |
Dec 31, 2020 | 24,300 | 900 | 3.85% |
Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
Dec 31, 2018 | 21,500 | 700 | 3.37% |
Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
Dec 31, 2015 | 17,900 | 0 | - |
Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
Dec 31, 2012 | 18,000 | 200 | 1.12% |
Dec 31, 2011 | 17,800 | 400 | 2.30% |
Dec 31, 2010 | 17,400 | 200 | 1.16% |
Dec 31, 2009 | 17,200 | 300 | 1.78% |
Dec 31, 2008 | 16,900 | -600 | -3.43% |
Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
Dec 31, 2001 | 7,700 | 400 | 5.48% |
Dec 31, 2000 | 7,300 | 900 | 14.06% |
Dec 31, 1999 | 6,400 | 900 | 16.36% |
Dec 31, 1998 | 5,500 | 192 | 3.62% |
Dec 31, 1997 | 5,308 | 662 | 14.25% |
Dec 31, 1996 | 4,646 | 600 | 14.83% |
Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMGN News
- 2 days ago - Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers - CNBC
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts - WSJ
- 3 days ago - Amgen to sell cholesterol drug at 60% discount direct to US consumers - Reuters
- 3 days ago - AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. - PRNewsWire
- 5 days ago - October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy - Seeking Alpha
- 7 days ago - LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS - PRNewsWire
- 8 days ago - Amgen Shares Cross Above 200 DMA - Forbes